DECITABINE + CEDAZURIDINE
Manner of administration:Oral
Restriction (Streamlined authority code: 13258)
Indication: Acute Myeloid Leukaemia
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 5 | # of repeats: 5 | DPMQ: $4,862.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Inqovi 35/100 | |||||
Manner of administration:Oral
Restriction
Indication: Myelodysplastic syndrome
Treatment phase: Initial treatment
Restriction
Indication: Acute Myeloid Leukaemia
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 5 | # of repeats: 2 | DPMQ: $4,862.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Inqovi 35/100 | |||||
Manner of administration:Oral
Restriction
Indication: Myelodysplastic syndrome
Treatment phase: Continuing treatment
Restriction
Indication: Chronic Myelomonocytic Leukaemia
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 5 | # of repeats: 5 | DPMQ: $4,862.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Inqovi 35/100 | |||||
Manner of administration:Oral
Restriction
Indication: Chronic Myelomonocytic Leukaemia
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 5 | # of repeats: 2 | DPMQ: $4,862.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Inqovi 35/100 | |||||